News of Note—GeoVax, Inovio, BiondVax and more

In this week's news of note, GeoVax named a new CEO. (Pixabay)

Here is some other vaccine news of note for the week:

> GeoVax announced that its president and CEO Robert McNally is retiring at the end of the month, and that industry veteran David Dodd will take the role effective Sept. 1. McNally will remain on the company's board. Release

> Inovio Pharmaceuticals kicked off a phase 1/2 study of a therapeutic HIV vaccine called Pennvax-GP. Release

> Investigators have enrolled the first patient in a phase 3 trial of BiondVax's universal flu vaccine candidate. Release

> A study published in Pediatrics found that children of mothers who received a prenatal Tdap vaccination were not more likely to be born with autism. Washington Post article